IPSC-GDNKT / CytoMed Therap - LARVOL DELTA

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology (PRNewswire-Asia) - "CytoMed Therapeutics Limited...announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA)....The patent...with Patent No. ZL201880022790.X, published as CN 110691844 B, covers technologies to derive novel synthetic γδ NKT cells for the treatment of various types of cancers including hematological malignancies and solid tumors. This asset is currently under preclinical development."

Patent • Hematological Malignancies • Solid Tumor

The IPO Buzz: China & Malaysia in April’s Micro-Cap Mix (IPOScoop.com) - "CytoMed expects to recruit its first patient in the second half of 2023 for the ANGELICA clinical trial of its CTM-N2D drug candidate in Singapore. The company expects to begin pre-clinical studies after 2024 for its other leading drug candidate program – its iPSC-gdNKT platform."

Preclinical • Trial status • Hematological Malignancies • Oncology • Solid Tumor

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering (PRNewswire) - "CytoMed Therapeutics Limited...announced the pricing of its initial public offering of its 2,412,369 ordinary shares at a price of US$4.00 per share, for gross proceeds of US$9,649,476.00 before deducting underwriting discounts, commissions and offering expenses....The net proceeds from the initial public offering will be used to advance the clinical development of the Company's CTM-N2D product candidate; to continue technology development of the Company's iPSC-gdNKT product candidate; to advance clinical development of the Company's CTM-GDT product candidate; and the remainder to fund R&D activities and manufacturing expansion, and for working capital and general corporate purposes."

Financing • Oncology • Solid Tumor